Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002422 · ClinicalTrials.gov registry record · Phase 1
A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy
A Phase 1 study of HIV Infections, sponsored by Harbor Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 6
- Study locations
NCT00002422 is a Phase 1 study of HIV Infections that has completed, run by Harbor Therapeutics. The registered enrollment target is 42 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT00002422, a Phase 1 study of HIV Infections, has completed, sponsored by Harbor Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give HE2000, an experimental anti-HIV drug, to HIV-infected patients on salvage therapy (emergency treatment used when a patient has not responded to standard therapy). HE2000 is a hormone that is suspected to make it more difficult for HIV to live in cells.
Conditions Studied
Interventions
- DRUG HE2000
Study Locations (6)
California
- ViRx Inc - Palm Springs
- Veterans Affairs Palo Alto Health Care Ctr - Palo Alto
- Quest Clinical Research - San Francisco
Illinois
- Northwestern Univ Med School - Chicago
New York
- St Vincents Hosp / Clinical Research Program - New York
Texas
- Plaza Med Ctr - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002422
The ClinicalTrials.gov registry entry for NCT00002422 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (91% lower). The listed sponsor is Harbor Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which HE2000 is the first listed.
NCT00002422 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT00002422 about?
NCT00002422 is a clinical study titled "A Study on the Safety and Anti-HIV Activity of HE2000 in HIV-Infected Patients on Salvage Therapy". The purpose of this study is to see if it is safe and effective to give HE2000, an experimental anti-HIV drug, to HIV-infected patients on salvage therapy (emergency treatment used when a patient has not responded to standard therapy). HE2000 is a hormone that is suspected to make it more difficult...
What is the current status of trial NCT00002422?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants.
What conditions does trial NCT00002422 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002422?
The interventions under investigation include: HE2000 (DRUG).
Who is sponsoring clinical trial NCT00002422?
This trial is sponsored by Harbor Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002422 being conducted?
This trial has 6 study locations across California, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.